The NCD Alliance is a formal alliance of the International Diabetes Federation, The International Union Against Tuberculosis and Lung Disease, Union for International Cancer Control and the World Heart Federation established on 19 May 2009 "representing the four main NCDs outlined in the World Health Organization’s 2008-2013 Action Plan for NCDs – cardiovascular disease, diabetes, cancer, and chronic respiratory disease".
Good Jeff's new firm - Rabin Martin, part of extensive web of PR firms working with corporate clients on global health issuesSubmitted by James Love on 18. September 2011 - 6:46
On July 19, I read a press release that annouced that:
IIPI side event at WIPO to present on a joint USPTO/IIPI project on "Missed Opportunities Patenting in Developing Countries"Submitted by thiru on 5. May 2011 - 5:04
The International Intellectual Property Institute (IIPI) is holding a side event at WIPO today on the margins of the WIPO Committee on Development and Intellectual Property (CDIP) on "Missed Opportunities for Patenting in Developing Countries" and "Innovation Opportunities in the Philippines".
The program flyer for the event notes that this initiative is a "joint project between the Intellectual Property Institute (IIPI) and the U.S. Patent and Trademark Office (USPTO)."
See update at the end. ----------
- Amy T Wang, Christopher P McCoy, Mohammad Hassan Murad and Victor M Montori, "Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review," British Medical Journal, cite as BMJ 2010;340:c1344, doi:10.1136/bmj.c1344, 18 March 2010.
On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.
The following are a few notes on PhRMA's revolving door with the federal government.
Billy Tauzin. Former member of Congress from Louisiana.
Chris Singer. Previously served as a professional staff member for the U.S. House Appropriations Committee.
Brian Toohey. Former Desk Officer and Deputy Director in the European Office of the U.S. Department of Commerce.
Billy Tauzin announced today that he will be stepping down as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of June 2010.
PhRMA's 990 Tax Return Form, Schedule J-1 shows the amount Tauzin was compensated in 2008:
Base compensation: $2,055,445
Bonus & incentive compensation: $692,875
Other reportable compensation: $159,412
Deferred compensation: $1,556,960
Nontaxable benefits: $11,465
In the United States, tax exempt non-profit organizations are subject some some requirements for financial disclosure via the IRS form 990, which is available to the public. The disclosure requirements cover most U.S. based trade associations, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade association for some 28 "member" companies.